⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL181202 | 0.72 | — | — | |
| SCHEMBL1751567 | 0.72 | — | — | |
| SCHEMBL35847 | 0.72 | — | — | |
| SCHEMBL19292 | 0.72 | — | — | |
| Methylene Chloride SCHEMBL669175 | 0.72 | — | — | |
| SCHEMBL17537090 | 0.67 | — | — | |
| 1,2-Dichloroethane SCHEMBL916016 | 0.67 | — | — | |
| SCHEMBL14721582 | 0.62 | — | — | |
| SCHEMBL15179655 | 0.62 | — | — | |
| 1,2-Dichloroethane SCHEMBL944798 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250197403-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| EP-4107166-A1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| WO-2011017395-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010135424-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |